KR880007082A - 제약 조성물 - Google Patents

제약 조성물 Download PDF

Info

Publication number
KR880007082A
KR880007082A KR1019870014699A KR870014699A KR880007082A KR 880007082 A KR880007082 A KR 880007082A KR 1019870014699 A KR1019870014699 A KR 1019870014699A KR 870014699 A KR870014699 A KR 870014699A KR 880007082 A KR880007082 A KR 880007082A
Authority
KR
South Korea
Prior art keywords
disease
active ingredient
pharmaceutical composition
pyrano
dioxo
Prior art date
Application number
KR1019870014699A
Other languages
English (en)
Other versions
KR960001370B1 (ko
Inventor
에이.알.클라크
피.라이트
제이.에이취.래트클리프
Original Assignee
피존즈 피엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630769A external-priority patent/GB8630769D0/en
Priority claimed from GB868630767A external-priority patent/GB8630767D0/en
Priority claimed from GB868630904A external-priority patent/GB8630904D0/en
Priority claimed from GB878706684A external-priority patent/GB8706684D0/en
Application filed by 피존즈 피엘시 filed Critical 피존즈 피엘시
Publication of KR880007082A publication Critical patent/KR880007082A/ko
Application granted granted Critical
Publication of KR960001370B1 publication Critical patent/KR960001370B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

내용 없음.

Description

제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 결막염, 각막염, '알레르기성 안질', 아데노비루스감염, 각막 동종이식 거부, 전포도막염, 비용(鼻茸), 혈관운동신경성비염, 비인강의 알레르기성 발현, 가역성 폐쇄 기도 질병, 크론병, 원심성 대장염 및 직장항문염으로 되는 군 중에서 선택된 질병을 가진 환자에게 유효성분으로서 9－에틸－6,9－디히드로－4,6－디옥소－10－프로필－4H－피라노(3,2,－g) 퀴놀린－2,8－디카르복실산 또는 그의 제약상 허용되는 염을 함유하는 수용액의 치료적 유효량을 투여하는 것을 특징으로 하는 치료방법.
  2. 제1항에 있어서, 질병이 결막염, 각막염, '알레르기성 안질', 아데노비루스 감염, 각막 동종이식 거부 및, 전포도막염 중에서 선택된 안(眼) 질병인 것을 특징으로 하는 방법.
  3. 제1항에 있어서, 질병이 비용(鼻茸), 혈관운동 신경성 비염, 비연강의 알레르기성 발현 중에서 선택된 비강내 질병인 것을 특징으로 하는 방법.
  4. 제1항에 있어서, 질병이 가역성 폐쇄 기도 질병인 것을 특징으로 하는 방법.
  5. 제1항에 있어서, 질병이 크론병, 원심성 대장염 및 직장항문염 중에서 선택된 하부의 장(腸) 질환인 것을 특징으로 하는 방법.
  6. 제1항에 있어서, 유효 성분이 네도크로밀 나트륨인 것을 특징으로 하는 방법.
  7. 유효 성분으로서 9－에틸－6,9－디히드로－4,6－디옥소－10－프로필－4H－피라노(3,2g) 퀴놀린－2,8－디카르복실산 또는 그의 제약상 허용되는 염을 함유하며, 3.5 내지 6의 pH를 갖는 수용액으로 되는 것을 특징으로 하는 제약 조성물.
  8. 제7항에 있어서, 용액 중의 유효 성분의 농도가 0.1 내지 5%W/V인 것을 특징으로 하는 제약 조성물.
  9. 제7항에 있어서, 용액이 또한 점도 조절제를 함유하며, 50초－1의 전단 속도에서 100 내지 10000cps의 점도를 갖는 것을 특징으로 하는 제약 조성물.
  10. 유효 성분으로서 9－에틸－6,9－디히드로－4,6－디옥소－10－프로필－4H－피라노(3,2－g) 퀴놀린－2,8－디카르복실산 또는 그의 제약상 허용되는 염을 함유하는 수용액의단위 복용량으로 충전시키고, 밀봉시킨 멸균 플라스틱 재료의 연질 앰풀제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870014699A 1986-12-23 1987-12-22 제약 조성물 KR960001370B1 (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB87/06684 1986-03-20
GB86-30769 1986-12-23
GB868630769A GB8630769D0 (en) 1986-12-23 1986-12-23 Pharmaceutical formulation
GB86/30769 1986-12-23
GB86-30767 1986-12-23
GB86/30767 1986-12-23
GB868630767A GB8630767D0 (en) 1986-12-23 1986-12-23 Pharmaceutical formulation
GB86-30904 1986-12-24
GB86/30904 1986-12-24
GB868630904A GB8630904D0 (en) 1986-12-24 1986-12-24 Pharmaceutical formulation
GB878706684A GB8706684D0 (en) 1987-03-20 1987-03-20 Pharmaceutical formulation
GB87-06684 1987-03-20

Publications (2)

Publication Number Publication Date
KR880007082A true KR880007082A (ko) 1988-08-26
KR960001370B1 KR960001370B1 (ko) 1996-01-26

Family

ID=27449862

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870014699A KR960001370B1 (ko) 1986-12-23 1987-12-22 제약 조성물

Country Status (22)

Country Link
US (1) US5443833A (ko)
EP (1) EP0279121B1 (ko)
JP (2) JP2568233B2 (ko)
KR (1) KR960001370B1 (ko)
AU (1) AU595969B2 (ko)
BE (2) BE1002179A5 (ko)
CA (1) CA1296635C (ko)
CH (1) CH674937A5 (ko)
DE (1) DE3787274T2 (ko)
DK (1) DK175032B1 (ko)
ES (1) ES2058129T3 (ko)
FI (1) FI875616A (ko)
FR (1) FR2609392B1 (ko)
GR (1) GR871999B (ko)
IE (3) IE63213B1 (ko)
IL (1) IL84893A (ko)
LU (1) LU87087A1 (ko)
MY (1) MY101535A (ko)
NO (1) NO875359L (ko)
NZ (1) NZ223026A (ko)
PT (1) PT86455B (ko)
SA (1) SA90110074B1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704773D0 (en) * 1987-02-28 1987-04-01 Fisons Plc Compounds
GB2202145B (en) * 1987-03-17 1991-01-02 Fisons Plc Compositions of nedocromil for dermatological use.
GB8727590D0 (en) * 1987-11-25 1987-12-31 Fisons Plc Formulation
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
CA2781923C (en) * 2009-12-03 2018-08-14 Opko Health, Inc. Hypersulfated disaccharide formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782473B (en) * 1977-05-04 1979-04-25 Fisons Ltd Benzo pyrano-quinolinones
US4474787A (en) * 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
IL54614A (en) * 1977-05-04 1983-07-31 Fisons Ltd Dihydrodioxo-pyranoquinoline dicarboxylic acid derivatives,their production and pharmaceutical compositions containing them
FR2440371A1 (fr) * 1978-10-31 1980-05-30 Fisons Ltd Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer
ATE11774T1 (de) * 1979-12-07 1985-02-15 Fisons Plc Verfahren zur herstellung von 1,4-dihydro-4-oxo- chinolin-2-carbonsaeuren oder salzen, estern oder amiden davon und zwischenverbindungen dafuer.
AU8468782A (en) * 1981-06-25 1983-01-06 Fisons Plc Compounds with sodium cromoglycate activity
GB8402047D0 (en) * 1984-01-26 1984-02-29 Fisons Plc Nitrogen heterocycles
EP0162556B1 (en) * 1984-04-13 1991-11-06 FISONS plc Novels forms and formulations of nedocromil sodium
GB8630419D0 (en) * 1986-12-19 1987-01-28 Fisons Plc Pharmaceutical formulation
GB8704089D0 (en) * 1987-02-21 1987-03-25 Fisons Plc Method of treatment
GB8704773D0 (en) * 1987-02-28 1987-04-01 Fisons Plc Compounds
GB2202145B (en) * 1987-03-17 1991-01-02 Fisons Plc Compositions of nedocromil for dermatological use.

Also Published As

Publication number Publication date
NO875359L (no) 1988-06-24
CA1296635C (en) 1992-03-03
JP2568233B2 (ja) 1996-12-25
KR960001370B1 (ko) 1996-01-26
PT86455B (pt) 1990-11-20
DE3787274D1 (de) 1993-10-07
IE873507L (en) 1988-06-23
IL84893A0 (en) 1988-06-30
IE63213B1 (en) 1995-04-05
DK680787D0 (da) 1987-12-22
IE940371L (en) 1988-06-23
MY101535A (en) 1991-11-30
LU87087A1 (fr) 1989-07-07
DE3787274T2 (de) 1994-01-27
GR871999B (en) 1988-04-26
SA90110074B1 (ar) 2006-03-06
IE940372L (en) 1988-06-23
AU8292987A (en) 1988-06-23
NZ223026A (en) 1989-09-27
BE1003466A3 (fr) 1992-03-31
US5443833A (en) 1995-08-22
EP0279121B1 (en) 1993-09-01
DK175032B1 (da) 2004-05-03
JP2504926B2 (ja) 1996-06-05
BE1002179A5 (fr) 1990-10-02
ES2058129T3 (es) 1994-11-01
JPS63233918A (ja) 1988-09-29
JPH07231926A (ja) 1995-09-05
EP0279121A2 (en) 1988-08-24
FR2609392B1 (fr) 1994-04-08
NO875359D0 (no) 1987-12-21
FI875616A (fi) 1988-06-24
IL84893A (en) 1991-11-21
PT86455A (en) 1988-01-01
FR2609392A1 (fr) 1988-07-15
CH674937A5 (ko) 1990-08-15
FI875616A0 (fi) 1987-12-21
DK680787A (da) 1988-06-24
AU595969B2 (en) 1990-04-12
EP0279121A3 (en) 1990-09-12

Similar Documents

Publication Publication Date Title
DK0495421T3 (da) Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
DE69129110D1 (de) Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
NO176346C (no) Fremgangsmåte ved fremstilling av en flytende, vandig farmasöytisk blanding for öye- og/eller nasal administrasjon
PT87542A (pt) Process for the preparation of a medicament based on indolone derivatives for the treatment of the parkinson disease
KR880007084A (ko) 제약 조성물
KR960021032A (ko) 연성 젤라틴 약제학적 용량형
KR880007082A (ko) 제약 조성물
KR880007514A (ko) 키놀린 화합물
KR890001584A (ko) Gh-분비호르몬, 콜린성 효능제 및 경우에 따라 담즙산염을 함유하는 비내 투여용 약제 조성물
ATE55248T1 (de) Arzneimittelkombination.
KR890007740A (ko) 제약학적 조성물
IT1226637B (it) Composizioni farmaceutiche a base di nedocromil sodio, metodi per la loro preparazione, e loro uso
EP0258476B1 (en) Aldose reductase inhibitors useful in glaucoma therapy
FI903531A0 (fi) Menetelmä lääkeaineina käyttökelpoisten 2-imino-3-heterosyklyylialkyylibentsotiatsoliinijohdannaisten valmistamiseksi
DE3264303D1 (en) 1-furyl-3,4-dihydroisoquinolines, process for their preparation, their use and medicines containing them
KR927003536A (ko) 키누렌산 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물
FR2597102B1 (fr) Derives de l'acide a-(hydroxy-7 tetrahydro-4,5,6,7 thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
IE791205L (en) Novel oxothia compounds, processes for their preparation,¹pharmaceutical preparations containing these compounds and¹such compounds for therapeutic use
KR880007077A (ko) 조성물
EP0396169A2 (en) Pharmaceutical composition for topical ophthalmic use having improved local tolerability
FR2588258B1 (fr) Nouveaux derives d'amino-5 valeronitrile, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
FR2572404B2 (fr) Nouveaux derives de l'acide 4-oh-3-quinoleine carboxylique substitues en 2, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
SU427712A1 (ru) Лекарственное средство

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060123

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee